API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. KQ /
  3. 347850.KQ

D&D PharmaTech Co. (347850 KQ) stock market data APIs

₩33550 -3350(-9.1%) as of November 25, 2024
Price chart is built with Anychart

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson's disease (PD), Alzheimer's disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical trials to treat NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03 that is in Phase I clinical trials for the treatment of PD, AD, and neuroinflammation; PMI04, which is in Phase I clinical trials to treat PD, AD, ALS, and depression; and PMI05 and PMI06 that are in Phase I clinical trials for the treatment of oncology and immuno-oncology. Its preclinical drug candidates include NLY03 for stroke/PD; DD03 to treat obesity and NASH; TLY014 for the treatment of tumor microenvironment; PMI31 for various cancers; and VT01 to treat PD. In addition, the company develops NLY02 for the treatment of PD & AD; NLY12 for type 2 diabetes and obesity; DD02 to treat type 2 diabetes; PMI21 for the treatment of prostate cancer; and PMI07 for oncology and fibrosis. Further, it focuses on the application of big data in CNS drug research and diagnostics. The company was founded in 2014 and is based in Seongnam-si, South Korea.

D&D PharmaTech Co. Financial Data Overview

36900
33550
-
37250
33550
25100-53900
0
0
0
-569.3194
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '347850',
Type: 'Common Stock',
Name: 'D&D PharmaTech Co.',
Exchange: 'KQ',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
OpenFigi: 'BBG01L0XW9P7',
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

D&D PharmaTech Co. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get D&D PharmaTech Co. Earnings via APIs

  • Latest Release 2024-06-30
  • EPS/Forecast NaN

Get D&D PharmaTech Co. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com